Senators question Allergan CEO on tribe patent deal
November 07, 2017 at 15:11 PM EST
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|